VEGFA and wet macular degeneration: In wet AMD, if the new drug is to be compared with the current standard of care (aflibercept 2 mg being the most common anti-VEGF comparator), it would be challenging for many patients to have 15 letters loss on aflibercept 2 mg, so it would be likely that the sponsor (drug company) would go for an endpoint of 15 letter gain.